Zobrazeno 1 - 10
of 41
pro vyhledávání: '"Raphael P Luber"'
Autor:
Raphael P Luber, Alexa Duff, Polychronis Pavlidis, Sailish Honap, Susanna Meade, Shuvra Ray, Simon H Anderson, Joel Mawdsley, Mark A Samaan, Peter M Irving
Publikováno v:
JGH Open, Vol 6, Iss 1, Pp 76-84 (2022)
Abstract Background and Aim Patients with chronic diseases are believed to be at increased risk of mental health conditions during the COVID‐19 pandemic. We aimed to assess the incidence of psychological morbidity in inflammatory bowel disease (IBD
Externí odkaz:
https://doaj.org/article/1083fc29a8d843a1b3bb2d0d1a90979f
Publikováno v:
Journal of Medical Case Reports, Vol 13, Iss 1, Pp 1-4 (2019)
Abstract Introduction Gastric adenocarcinoma is a known complication of partial gastrectomy. Jaundice from gastric adenocarcinoma usually occurs in the setting of hepatic nodal or parenchymal metastasis. This case demonstrates an unusual level of bil
Externí odkaz:
https://doaj.org/article/e28ec3cd70764e0dbe05e610e7b7ca8f
Publikováno v:
Frontiers in Medicine, Vol 6 (2019)
Thiopurines are a cheap, effective treatment option in the management of inflammatory bowel disease (IBD). However, with the growing choice of targeted therapies available, as well as the well-documented toxicities of thiopurines, the role of thiopur
Externí odkaz:
https://doaj.org/article/7d917c012db345f9b2f15af8111d614d
Autor:
Raphael P. Luber, Clarissa Rentsch, Steve Lontos, Jeffrey D. Pope, Ar Kar Aung, Hans G. Schneider, William Kemp, Stuart K. Roberts, Ammar Majeed
Publikováno v:
Case Reports in Hepatology, Vol 2019 (2019)
Turmeric is a commonly used oral herbal supplement with purported anti-inflammatory and antineoplastic properties. It is promoted as safe, with limited reports of severe adverse effects directly related to oral turmeric thus far in the literature. He
Externí odkaz:
https://doaj.org/article/78d2f576e2ea444b83b72eebff924a0d
Autor:
Susanna Meade, Kamal V. Patel, Raphael P. Luber, Dearbhaile O'Hanlon, Andra Caracostea, Polychronis Pavlidis, Sailish Honap, Cheran Anandarajah, Nyree Griffin, Sebastian Zeki, Shuvra Ray, Joel Mawdsley, Mark A. Samaan, Simon H. Anderson, Amir Darakhshan, Katie Adams, Andrew Williams, Jeremy D. Sanderson, Miranda Lomer, Peter M. Irving
Publikováno v:
Alimentary Pharmacology & Therapeutics. 56:646-663
Low-quality evidence suggests that pre-operative exclusive enteral nutrition (E/EN) can improve postoperative outcomes in patients with Crohn's disease (CD). It is not standard practice in most centres.To test the hypothesis that pre-operative EN in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3eacc5aa0dc309c298a37eb09f5f1a1a
https://doi.org/10.1111/apt.17055
https://doi.org/10.1111/apt.17055
Autor:
Clarissa A. Rentsch, Mark G. Ward, Raphael P. Luber, Kirstin M. Taylor, David J. Gibson, Belinda Headon, Ourania Rosella, Heidi Y. Su, Antony B. Friedman, Michael Dooley, Miles P. Sparrow, Peter R. Gibson
Publikováno v:
Therapeutic drug monitoring.
Therapeutic monitoring of infliximab is limited by the time lag between drug-level measurement and dose adjustment, along with the cost of dose escalation. Strategies for dose reduction in stable patients on maintenance infliximab at supratherapeutic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::58d438167faa9f2319c0522ca1871c95
https://pubmed.ncbi.nlm.nih.gov/36174193
https://pubmed.ncbi.nlm.nih.gov/36174193
Autor:
Raphael P Luber, Bianca Petri, Susanna Meade, Sailish Honap, Sebastian Zeki, Krisztina B Gecse, Nyree Griffin, Peter M Irving
Publikováno v:
Frontline gastroenterology, 14(1):flgastro-2022-102156, 52-58. BMJ Publishing Group
ObjectiveIntestinal ultrasound (IUS) is an inexpensive, non-invasive method of diagnosing and monitoring inflammatory bowel disease (IBD). We aimed to establish the proportion of lower gastrointestinal endoscopies (LGIEs) and magnetic resonance enter
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ef358504d4efcc07c94d6a8fb317fd22
https://pure.amc.nl/en/publications/positioning-intestinal-ultrasound-in-a-uk-tertiary-centre(e390a260-663b-4806-b578-26d65bf2a78a).html
https://pure.amc.nl/en/publications/positioning-intestinal-ultrasound-in-a-uk-tertiary-centre(e390a260-663b-4806-b578-26d65bf2a78a).html
Autor:
Susanna Meade, Raphael P. Luber, Gokul Tamilarasan, Eoin Dinneen, Peter M. Irving, Mark A. Samaan
Publikováno v:
European Medical Journal, Vol 6, Iss 1, Pp 49-58 (2021)
It was predicted that the biological era might alter the natural history of Crohn’s disease, preventing the well-documented inflammation–fibrosis–fistulisation sequence. However, despite the development of novel biological therapies, average ef
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doajarticles::8c1e00a54e847b44bbabe10d40cb5c1f
https://www.emjreviews.com/gastroenterology/article/emerging-treatments-for-crohns-disease-cells-surgery-and-novel-therapeutics/
https://www.emjreviews.com/gastroenterology/article/emerging-treatments-for-crohns-disease-cells-surgery-and-novel-therapeutics/
Autor:
Andra Caracostea, Joel Mawdsley, Simon Anderson, Anna Stanton, Dearbhaile O’Hanlon, Shuvra Ray, Mark A Samaan, Sebastian Zeki, Polychronis Pavlidis, Sherill Tripoli, Esha Sharma, Sailish Honap, Peter M. Irving, Jeremy D. Sanderson, Alexa Duff, Susanna Meade, Rebecca Reynolds, Francesca D'Errico, Raphael P. Luber, Katie Hill
Publikováno v:
GastroHep
Gastrohep
Gastrohep
Background To quantify the effects of COVID‐19 on our inflammatory bowel disease (IBD) unit, including service provision, prescribing practices and use of therapeutic drug monitoring (TDM). Methods We performed a single centre retrospective observa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1affa0af33e9e1cfc7ca8e264e3fda3c
https://doi.org/10.1002/ygh2.433
https://doi.org/10.1002/ygh2.433
Autor:
Tony Long, Anna Wan, Declan Connoley, Maria Bishara, Danny Con, Peter R. Gibson, Abhinav Vasudevan, James A Rickard, Neetima Joshi, Daniel R. van Langenberg, Nina Parthasarathy, Raphael P. Luber, Miles P. Sparrow
Publikováno v:
Journal of Crohn's and Colitis. 15:583-593
Background Early or first-line treatment with biologics, as opposed to conventional immunomodulators, is not always necessary to achieve remission in Crohn’s disease [CD] and may not be cost-effective. This study aimed to develop a simple model to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::40c771458268f30ec1ddad6eb355b470
https://doi.org/10.1093/ecco-jcc/jjaa194
https://doi.org/10.1093/ecco-jcc/jjaa194